Advertisement

Pfizer embraces stem cells

Big pharma's interest in linkurl:stem cell research;http://www.the-scientist.com/blog/display/54900/ is picking up speed. Pharmaceutical giant Pfizer is expanding its research into the technology and plans to open a second regenerative medicine unit in Cambridge, UK, this November, Reuters linkurl:reported;http://www.reuters.com/article/reutersEdge/idUSTRE48MBY020080923?sp=true yesterday. Pfizer isn't the only one. In July, GlaxoSmithKline entered a linkurl:5-year, $25 million collaboration;ht

By | September 24, 2008

Big pharma's interest in linkurl:stem cell research;http://www.the-scientist.com/blog/display/54900/ is picking up speed. Pharmaceutical giant Pfizer is expanding its research into the technology and plans to open a second regenerative medicine unit in Cambridge, UK, this November, Reuters linkurl:reported;http://www.reuters.com/article/reutersEdge/idUSTRE48MBY020080923?sp=true yesterday. Pfizer isn't the only one. In July, GlaxoSmithKline entered a linkurl:5-year, $25 million collaboration;http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10089.htm with the Harvard Stem Cell Institute. In the spring, Pfizer opened a regenerative medicine unit in Cambridge, Massachusetts, focusing on stem cells for cardiac disorders and cancer, according to the linkurl:company's Web site.;http://www.pfizer-regenerativemedicine.com/locations/index.php The new UK site will eventually house 60 scientists and research will focus on age-related and degenerative and nervous system disorders. While Pfizer's stem cell research policy does not rule out the use of embryonic stem cells, the company is also extremely interested in induced pluripotent stem (iPS) cells, John McNeish, head of the Massachusetts operation, told Reuters at the World Stem Cell Summit, held this week in Madison, Wisconsin. In June, Pfizer also entered a linkurl:$3 million partnership;http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&newsId=20080623005677&newsLang=en with EyeCyte, Inc., a California company whose technology uses blood and bone marrow progenitor cells to treat retinal diseases.
Advertisement

Popular Now

  1. The Sum of Our Parts
    Features The Sum of Our Parts

    Putting the microbiome front and center in health care, in preventive strategies, and in health-risk assessments could stem the epidemic of noncommunicable diseases.

  2. Most Earth-like Planet Found
  3. Ancient Viruses as Gene Therapy Vectors
  4. Judge Decides on GM Rice Retraction
Advertisement
PDA
PDA
Advertisement